Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Plain-language summary

This study looks at how the drugs Dactinomycin and Vincristine behave in the body in children and young patients receiving them as part of cancer treatment, using pharmacological and biomarker analyses. People receiving these drugs for cancers such as acute lymphoblastic leukemia, Ewing sarcoma, rhabdomyosarcoma or Wilms tumor could take part. This was a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Children's Oncology Group

Intervention

pharmacological study, laboratory biomarker analysis

Start date

2/1/2008

Countries

United States, Australia, Canada

Related genes

Locations

• Birmingham, United States
• Long Beach, United States
• Los Angeles, United States
• Orange, United States
• San Diego, United States
• San Francisco, United States
• Hartford, United States
• Washington D.C., United States
• Jacksonville, United States
• Orlando, United States
• Tampa, United States
• Chicago, United States
• Chicago, United States
• Oak Lawn, United States
• Indianapolis, United States
• Louisville, United States
• Boston, United States
• Ann Arbor, United States
• St Louis, United States
• New York, United States
• Asheville, United States
• Winston-Salem, United States
• Cleveland, United States
• Cleveland, United States
• Portland, United States
• Pittsburgh, United States
• Providence, United States
• Charleston, United States
• Knoxville, United States
• Memphis, United States
• Corpus Christi, United States
• Dallas, United States
• Houston, United States
• San Antonio, United States
• Seattle, United States
• Milwaukee, United States
• Perth, Australia
• Montreal, Canada

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of cancer, including, but not limited to, any of the following:

  * Acute lymphoblastic leukemia
  * Ewing sarcoma
  * Rhabdomyosarcoma
  * Soft tissue sarcoma
  * Wilms tumor
* Due to receive or receiving dactinomycin and/or vincristine as a component of cancer treatment on another clinical trial
* Able to comply with study requirements
* Other concurrent chemotherapeutic agents allowed